Anzeige
Mehr »
Login
Samstag, 25.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Achtung! Ist das die Krypto-Aktie des Jahres 2024 mit 700% Potential?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PM28 | ISIN: US3596161097 | Ticker-Symbol:
NASDAQ
24.05.24
22:00 Uhr
7,210 US-Dollar
-0,210
-2,83 %
1-Jahres-Chart
FULCRUM THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FULCRUM THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur FULCRUM THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.05.Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY62
14.05.Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug6
13.05.After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more29
13.05.Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)1
13.05.Fulcrum Therapeutics Inc reports results for the quarter ended in March - Earnings Summary1
13.05.Fulcrum Therapeutics up on licensing deal with Sanofi for muscle disorder drug2
13.05.Fulcrum Therapeutics GAAP EPS of -$0.43 in-line1
13.05.Fulcrum Therapeutics, Inc. - 10-Q, Quarterly Report1
13.05.Fulcrum Therapeutics, Inc. - 8-K, Current Report1
13.05.Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod3
13.05.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy63? Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ? ? Fulcrum will receive an upfront payment...
► Artikel lesen
06.05.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET1
22.03.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)129CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
18.03.Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer1
18.03.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer137?Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ? ?...
► Artikel lesen
08.03.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)58CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
► Artikel lesen
05.03.Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference1
28.02.Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)1
27.02.Fulcrum Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
27.02.Fulcrum Therapeutics, Inc. - 10-K, Annual Report2
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1